Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 22, 2026 07:00 ET | Source: SAB Biotherapeutics, Inc.

SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

All 4 T1D participants receiving SAB-142 showed C-peptide preservation with 3 of the 4 participants showing a super responder profile concomitant with T cell exhaustion T1D participants receiving...
April 15, 2026 08:00 ET | Source: SAB Biotherapeutics, Inc.

SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress

MIAMI, April 15, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type...
March 19, 2026 16:01 ET | Source: SAB Biotherapeutics, Inc.

SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

MIAMI, March 19, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type...
March 17, 2026 22:46 ET | Source: SAB Biotherapeutics, Inc.

SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type...
March 17, 2026 16:01 ET | Source: SAB Biotherapeutics, Inc.

SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type...
March 10, 2026 07:31 ET | Source: SAB Biotherapeutics, Inc.

SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes

Results demonstrated early signals of C-peptide preservation T1D key opinion leader, Michael J. Haller, MD, provided a recorded webinar reviewing the SAB-142 Phase 1 data MIAMI, March 10, 2026 ...
March 09, 2026 17:16 ET | Source: SAB Biotherapeutics, Inc.

SAB BIO Reports Full Year 2025 Financial Results and Business Highlights

Advanced SAB -142 into registrational Phase 2b SAFEGUARD study with multiple patients dosed; enrollment ongoing and on track to complete enrollment by end of 2026 with topline data expected in 2H 2027...
March 02, 2026 09:00 ET | Source: SAB Biotherapeutics, Inc.

SAB BIO to Participate in Upcoming Investor Conferences

MIAMI, March 02, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type...
February 04, 2026 09:00 ET | Source: SAB Biotherapeutics, Inc.

SAB BIO to Participate in Upcoming Investor Conferences

MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1...
January 07, 2026 08:00 ET | Source: SAB Biotherapeutics, Inc.

SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director

David Zaccardelli, Pharm.D. joins Board as Chair Rita Jain, M.D., joins Board as an Independent Director MIAMI, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a...